ReviewFrontiers in pharmacology2023
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Drug-microbiome-host interactions: antimicrobial effects of non-antibiotic compounds.Nature reviews. Gastroenterology & hepatology · 2026Review
- Influence of fluoxetine on the gastric healing process: experimental evidence of sexual dimorphism.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Proton pump inhibitor use is not independently associated with colonic diverticulosis in an asymptomatic screening population.Scientific reports · 2026Observational
- Proton pump inhibitor exposure modulates functional and transcriptional responses inFrontiers in cellular and infection microbiology · 2026Article
- Mechanisms of multi-organ damage in Wilson disease from the gut-liver-brain axis perspective: copper metabolism, gut microbiota, and metabolite communication.Frontiers in microbiology · 2026Review
- Exploring the etiology of colitis: insights from gut microbiota research.Gut microbes · 2025Review
- Proton-pump inhibitors increaseGut microbes · 2025Article
- The role of microbiota dysbiosis in Parkinson's disease: Pathophysiology and therapeutic opportunities.Engineering microbiology · 2025Review
- Association between acid-suppressant use and self-reported stroke.BMC neurology · 2025Article
- Lactiplantibacillus plantarum Moderating Effect on Autoimmune Celiac Disease Triggers.Probiotics and antimicrobial proteins · 2025Review
- Human Digestive Physiology and Evolutionary Diet: A Metabolomic Perspective on Carnivorous and Scavenger Adaptations.Metabolites · 2025Review
- Review
- M64HCl, a focal adhesion kinase activator, promotes intestinal mucosal healing in rats.BMC gastroenterology · 2025Article
- Antibiotic Cocktail Exacerbates Esomeprazole-Induced Intestinal Dysmotility While Ameliorating Gastric Dyspepsia in Mice.Antibiotics (Basel, Switzerland) · 2025Article
- Proton pump inhibitors and all-cause mortality risk among cancer patients.World journal of clinical oncology · 2025Article
- Microbial beginnings: determinants and disruptions of the neonatal microbiome.Frontiers in microbiology · 2025Review
- Microbiome influence in gastric cancer progression and therapeutic strategies.Frontiers in medicine · 2025Review
- The gut microbiota and aging: interactions, implications, and interventions.Frontiers in aging · 2025Review
- Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks.Current gastroenterology reports · 2024Review
- Critical analysis of the effects of proton pump inhibitors on inflammatory bowel disease: An updated review.World journal of gastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.